Liquidia Corp director Arthur S. Kirsch, through a revocable trust, reported open-market sales of an aggregate 30,000 shares of Liquidia common stock. The trust sold 15,000 shares on June 1, 2026 at a reported volume-weighted average price of about $60.22 per share, with a footnote stating trade prices ranged from $59.90 to $60.75.
The trust then sold 5,000 shares on June 2, 2026 at $56.00 per share and 10,000 shares on June 3, 2026 at $54.80 per share, leaving the trust with 0 indirectly held shares. A separate holding entry shows Kirsch with 40,755 shares held directly as of June 1, 2026.
Liquidia Corp Chief Executive Officer Roger Jeffs reported an open-market sale of 6,428 shares of common stock at a volume-weighted average price of $62.183 per share. The sale was executed indirectly through Serendipity BioPharma LLC pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.
Following the sale, Serendipity BioPharma LLC held 1,041,667 shares indirectly for Jeffs, in addition to 1,137,508 shares held directly and 46,595 shares held through the Roger A. Jeffs Living Trust. Jeffs also holds unvested restricted stock units granted between January 2023 and January 2026 that had not vested as of this Form 4.
Liquidia Corp director Raman Singh reported an exercise-and-sell transaction in company stock. On May 21, 2026, he sold 29,494 shares of Common Stock in an open-market sale at a volume-weighted average price of $60.1287, representing the subsequent sale of shares acquired from option exercises reported in the same filing.
That day he exercised stock options covering 10,050 shares at $11.00 per share and 19,444 shares at $8.63 per share. After these transactions, he directly holds 38,755 Common shares and has 18,396 restricted stock units that were granted on June 17, 2025 and have not yet vested.
Liquidia Corp Chief Executive Officer Roger Jeffs reported open-market sales of 75,000 shares of Common Stock across three transactions on May 21, 2026, May 22, 2026, and May 26, 2026. The sales were executed at volume-weighted average prices of $61.1264, $61.5222, and $60.3784 per share, respectively, and were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025.
The sold shares are reported as indirectly owned through entities including the Roger A. Jeffs Living Trust and Serendipity BioPharma LLC, where Jeffs has voting and dispositive power. After the most recent transaction, indirect holdings are reported at 1,048,095 shares, and a separate direct holding entry on May 21, 2026 shows 1,137,508 shares. Jeffs also holds multiple grants of unvested restricted stock units totaling more than 400,000 RSUs that have not yet vested.
Ramandeep Singh filed a Form 144 notifying the proposed sale of 29,494 shares of common stock via a stock option exercise to occur on 05/21/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker-dealer and Nasdaq as the market.
The notice also records a prior sale of 40,359 shares on 03/13/2026 for $1,457,296.50.
Liquidia Corp insider Caligan Partners and David Johnson reported internal fund transactions in the company’s common stock. On May 19, 2026, Caligan-managed entities recorded both an open-market purchase and an open-market sale of 5,300 shares each at $59.98 per share.
A footnote explains this represents a transaction between Caligan Funds, indicating a reallocation among affiliated investment vehicles rather than a directional change in overall exposure. After these trades, Caligan-related entities held 8,133,651 Liquidia shares indirectly, while David Johnson also held 18,396 shares directly.
Liquidia Corp CEO Roger Jeffs reported open-market stock sales executed under a pre-arranged trading plan. Entities associated with him sold a total of 75,000 shares of Liquidia common stock in three transactions on May 18–20, 2026, at volume-weighted average prices of about $56.77, $58.65, and $61.30 per share.
The shares were held indirectly through a living trust and Serendipity BioPharma LLC, where Jeffs serves as trustee or manager with voting and dispositive power. After these trades, his indirect holdings stood at 1,123,095 shares, and he also continues to hold a substantial direct position and multiple grants of unvested restricted stock units.
Serendipity Biopharma LLC and affiliated parties reported multiple Rule 144/10b5-1 dispositions of Common Stock. The excerpt lists scheduled 10b5-1 sales and Rule 144 sales executed between 04/09/2026 and 05/19/2026, with individual transactions commonly of 25,000 shares and reported dollar amounts per trade. The filings identify a broker-dealer intermediary as Morgan Stanley Smith Barney LLC.
Liquidia Corp Chief Executive Officer Roger Jeffs reported open-market sales totaling 75,000 shares of common stock over three days. The transactions, executed indirectly through entities he controls, occurred on May 13–15, 2026 at volume-weighted average prices of $56.2851, $58.6226 and $57.0429 per share.
Following these sales, he continues to hold 1,198,095 shares indirectly and 1,137,508 shares directly, along with multiple blocks of unvested restricted stock units granted between 2023 and 2026. The filing notes the trades were made under a pre-arranged Rule 10b5-1 plan adopted on November 5, 2025.